{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoIS73psLDA","lastupdate":"2024-10-28T00:00:00.000Z","update_date":"2024-10-28T00:00:00.000Z","lastModified":"Oct 29, 2024","active":1,"confidence_score":89,"confidence_score_reason":"video or image, markets, not claimed","urlname":"splisense","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$JS8BOpidhTStHuEfwGf2V21W0KNz5GXjgiN9ZmN2DYhE9sus6Sw3zY","name":"SpliSense","oneliner":"RNA-based Treatment for Genetic Diseases","registrar":"515535730","website":"https://splisense.com/","careerspage":"https://splisense.com/careers","founded_month":11,"founded_year":2016,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/77849119","instagram":""},"social":["https://www.linkedin.com/company/77849119"],"flattenedsociallinks":"https://www.linkedin.com/company/77849119","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"11-50","employees_exact":17,"patent":1,"raised":41500000,"stage":"B","public_stage":"B","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Spli Sense","Spli-Sense"],"about":"SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment is based on clinically validated Antisense Oligonucleotide (ASO) technology, delivered non-invasively by inhalation to the lungs.\n\nThe company is focused on a variety of innovative therapies, in different development stages from discovery to IND.\nUsing an innovative approach, SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and modulate proteins expression and function.\n\nThe company recieved FDA approval for its lead ASO product, SPL84, for the treatment of patients with cystic fibrosis.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"","country":null,"address":{"israeli":[{"id":"608d6333-9d7a-494f-8636-dca20707f653","city":"Jerusalem","type":null,"address":"Kalman Ya'akov Man St, Jerusalem, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Jerusalem District","news":[{"id":"CGhdOegHWHlTX0UmedhSdNRPgBmbswgxSKT7rFHuOPIap1inQsEhco","date":"Sep 3, 2025","link":"https://www.prnewswire.com/il/news-releases/splisense-reports-positive-results-from-phase-2-study-of-spl84-in-cystic-fibrosis-302544977.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"clinical trial","round":null,"company":"SpliSense","layoffs":null,"summary":"SpliSense, a clinical-stage biotechnology company, announced positive results from its Phase 2 study of SPL84, an antisense oligonucleotide therapy for cystic fibrosis (CF). The study showed improvements in lung function in up to 70% of participants, with no safety concerns identified. This marks the first evidence of potential clinical benefit of antisense oligonucleotide therapy in a pulmonary disease. The results validate SpliSenses platform, supporting the advancement of additional pulmonary programs into the clinic by early 2026. SPL84 has been granted Orphan Drug and Fast Track designations by the FDA, highlighting its potential to address unmet medical needs in CF treatment.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["pulmonary disease","antisense oligonucleotide","clinical trial","lung function","RNA therapy"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NGu6vNeQmunBdHXA2grchw2DVRqzIXmhtWy5lG8de1Qsch6egqnCiz","news_summary":"/PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"AcqwzbMZ03Qyc0RPd4Sg2xIc2KRTvjiHY7a4irJ472EiHx8TgpaiLA","date":"May 28, 2024","link":"https://www.prnewswire.com/news-releases/splisense-receives-fda-fast-track-designation-for-spl84-for-the-treatment-of-cystic-fibrosis-302157595.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA approval","company":"SpliSense","layoffs":null,"summary":"SpliSense, a biotechnology company specializing in RNA-based therapies for pulmonary diseases, announced that its lead product, SPL84, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). SPL84 is designed to treat cystic fibrosis (CF) patients with a specific genetic mutation. This designation will expedite the development and review process, potentially speeding up the delivery of this treatment to patients. The Fast Track status acknowledges the urgent need for effective treatments for CF, particularly for those with the 3849+10 Kb C->T mutation. SpliSenses approach involves using antisense oligonucleotides (ASOs) to correct mutations in the CFTR gene, aiming to restore normal protein function. SPL84 is currently in a global Phase 2 study.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["RNA therapies","Cystic fibrosis","FDA approval","Pulmonary diseases","Clinical trials"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IJUMUIPceslJ5lRVO8b1QxkQeZjxEksHCXGDaGodZFQPjAWF8JOeHE","news_summary":"SpliSense Receives FDA Fast Track Designation for SPL84 for the Treatment of Cystic Fibrosis","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"SPNrBZmpFkEffWyZYuquy6tHt8yOJAoQyvzYB7cHPUJg42PwyiNiGk","date":"Jan 4, 2022","link":"https://www.prnewswire.com/il/news-releases/splisense-announces-fda-and-ema-grant-orphan-drug-designation-to-spl84-23-1-for-the-treatment-of-cystic-fibrosis-301453367.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Drug Approval, Cystic Fibrosis Treatment","company":"SpliSense","layoffs":"Not mentioned","summary":"Biopharmaceutical company SpliSense has received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for SPL84-23-1, a therapy for cystic fibrosis (CF) and other pulmonary diseases. The ODD status, granted to drugs intended to treat rare diseases, provides companies with development incentives including tax credits for clinical trials, exemptions from FDA application fees, and potential marketing exclusivity for seven years following regulatory approval. SpliSense plans to commence clinical trials for SPL84-23-1 in mid-2022 in the US, Europe, and Israel.","partners":"FDA, EMA","customers":"Patients with cystic fibrosis","investors":"Not mentioned","confidence":9,"key_topics":["Orphan Drug Designation","Cystic Fibrosis","FDA","EMA","Clinical Trials"],"date_of_event":"Jan. 4, 2022","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Customers","Partners"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"lVoWI6lrfg9Z4mS1Ow64o0uHCgDhWeUnZBAVARujW1jCuVAl4ZNEpz","news_summary":"SpliSense Announces FDA and EMA Grant Orphan Drug Designation to SPL84-23-1 for the Treatment of Cystic Fibrosis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ftGrFzsXahivRFlPly4RqU1zL7rVrcHzJnnnaXT3EK7ZRfKh8DSUrP","date":"Jan 4, 2022","link":"https://www.jpost.com/health-and-wellness/article-691521","source":"www.jpost.com","visible":1,"analysis":{"tags":"orphan drug designation","company":"SpliSense","layoffs":null,"summary":"SpliSense, an Israeli biopharmaceutical company, announced that its cystic fibrosis treatment technology has received orphan drug designation from both the US FDA and the European Medicines Agency. This designation is a significant milestone for the company, as it aims to address the unmet needs of cystic fibrosis patients. The treatment, SPL84-23, is an antisense oligonucleotide designed to correct a specific mutation in the CFTR gene. The Cystic Fibrosis Foundation invested $8.4 million in SpliSenses technology, part of a $28.5 million funding round. The company plans to initiate clinical studies in the US, Europe, and Israel later this year.","partners":null,"customers":null,"investors":["Cystic Fibrosis Foundation"],"confidence":9,"key_topics":["Cystic Fibrosis","Orphan Drug","FDA","EMA","RNA"],"date_of_event":"January 4, 2022","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$28.5 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tIyyHvKJ7qAdRjOT5RQObbEByFnEBew5ufBom1W0kzwaUtcCxuHww2","news_summary":"Israeli firm SpliSense moves to clinical trials for cystic fibrosis treatment","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b5fc8bc5-8932-4e6c-b1a6-208d7eb5e22c","date":"Sep 13, 2021","link":"https://www.israel21c.org/inhaled-drug-could-treat-rare-cystic-fibrosis-mutations/","source":"www.israel21c.org","visible":1,"analysis":{"tags":["mRNA technology","cystic fibrosis","biotech company"],"company":"SpliSense","layoffs":null,"summary":"Jerusalem-based biotech company SpliSense is developing a new treatment for cystic fibrosis using mRNA technology. The companys technology manipulates defective messenger RNA to generate a fully functioning protein, offering hope for the 20% of CF patients with different genetic mutations. SpliSense has raised $28.5 million in a Series B round to fund clinical trials and the development of treatments for other pulmonary ailments. The treatment, based on Anti Sense Oligonucleotide (ASO), is meant to be inhaled and administered weekly for 10 minutes. SpliSense aims to address orphan conditions and potentially benefit the other 80% of CF patients. The first human clinical trials are planned for 2022.","partners":null,"customers":null,"investors":["Orbimed","Biotel Limited","Integra Holdings","Cystic Fibrosis Foundation"],"confidence":8,"key_topics":["Cystic fibrosis treatment","mRNA technology","ASO sequences","Orphan conditions","Clinical trials"],"date_of_event":"Late 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$28.5 million","structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"NVVxpQqMChJlkX9cZ3KZsxvWzZodxFKA3bhgmo6WAf7V2qnYT9iNA6","news_summary":"Inhaled drug could treat rare cystic fibrosis mutations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Vcjy5OhflyqkO51uE4YbYm9LRhSf7gMTQ6PQWIcD8iqLtaNbMoIM1y","date":"May 19, 2021","link":"https://cysticfibrosisnewstoday.com/news/splisense-28-5-million-financing-advance-aso-treatments-rare-cf-mutations/","source":"cysticfibrosisnewstoday.com","visible":1,"analysis":{"tags":["antisense oligonucleotide","genetic lung diseases","funding","CF treatment","ASO-based therapy"],"company":"SpliSense","layoffs":null,"summary":"SpliSense has raised $28.5 million in funding to advance its antisense oligonucleotide (ASO) platform for the treatment of cystic fibrosis (CF) caused by certain rare mutations, and of other genetic lung diseases. The funding will enable the exploration of synthetic ASOs as a potential treatment for CF, offering hope of restoring adequate lung function to CF patients. SpliSense plans to launch a Phase 1/2 clinical trial of its lead ASO, SPL84-23, in 2022. Other earlier-stage CF therapies being developed by the company include SPL23-2 and SPL24-N. The funding round featured investors such as Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings, and the Cystic Fibrosis Foundation.","partners":null,"customers":null,"investors":["Orbimed","Israel Biotech Fund","Biotel Limited","Integra Holdings","Cystic Fibrosis Foundation"],"confidence":9,"key_topics":["antisense oligonucleotide","cystic fibrosis","genetic lung diseases","funding","ASO-based therapy"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":28500000,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tddcn8UBbuppl50k6bo9mzSn01cGqMSGIrhVq5ZlRQ1OFbq1726gCw","news_summary":"SpliSense Raises $28.5M to Advance Treatments for Rare CF Mutations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[],"tags":["medical-technologies","pharma-companies","pharmaceuticals","biotechnology","drug-development","treatments","genetics"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"technologysuccessstory":[{"date":"2016-11-01","name":"Treatment of genetic diseases by targeting major splicing mutations","tags":["medication","genetic-disorders"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/yissum_tto_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6","university_logo":"/image_cloud/yissum_institution_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["SPL84","SPL5AC","SPL5B","SPL23"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":6,"lastfunding":"$12M","totalrounds":4,"fundingstage":"B","totalfunding":"$41.5M","publicinvestors":6,"lastpublicfunding":12000000,"totalpublicrounds":4,"totalpublicfunding":41500000},"team":[{"name":"Gili Hart","email":"gili@splisense.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4LXZw5kJDA","bounced":false,"claimed":0,"founder":0,"urlname":"gili-hart","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgzfid0QgM","position":"Acting CEO","last_name":"Hart","claimtoken":"xJ3A8ngt1I2e892qmPnPVLOYDq5kwZ4ewmwROkYSHyPgOL8UPoaaep","first_name":"Gili","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/gili-hart-57690911/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-10-28 18:41:49.000000","initials":"GH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Efrat Ozeri-Galai","email":"efrat@splisense.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Jb0j7IJDA","bounced":false,"claimed":0,"founder":0,"urlname":"efrat-ozeri-galai","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgpuTjoQkM","position":"VP R&D","last_name":"Ozeri-Galai","claimtoken":"hbTgBFwUVowpihPxOWLaZGXbaayumT3d2osLDXECR37f3VzxAGVtdK","first_name":"Efrat","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/efrat-ozeri-galai-b410372/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-10-28 18:41:53.000000","initials":"EO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yifat Oren","email":"yifat@splisense.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoLulotwJDA","bounced":false,"claimed":0,"founder":0,"urlname":"yifat-oren","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6_eEhQkM","position":"Head of Research","last_name":"Oren","claimtoken":"LK01BmTLFD4txUTxfFl9XSTMeLqCGekTTD5ZaB6MmZUMmQCzMQUWxo","first_name":"Yifat","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yifat-oren-381b8211/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2024-10-28 18:41:56.000000","initials":"YO","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-02-06T00:00:00.000Z","crunchbaseid":"splisense","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":"Jenny Sotnik-Talisman","creator_email":"genys30@yahoo.com","createdate":"2017-09-25T00:00:00.000Z","biverification":"Jenny Sotnik-Talisman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"bQLEeiU8IRxDxCkGBtEPBCCxeMk0gtqMyBg5ev63xt6dI30Pqss3nO","date":"Apr 2024","amount":"$12M","source":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_2566612_0_Txtetaxjxdshwhus8sp&did=1001476461","eventtype":"FundingRoundEvent","investment":[{"name":"Cystic Fibrosis Foundation","type":"Multinational","amount":8500000,"hidden":true,"country":"United States","fullurl":"/mnc_page/cystic-fibrosis-foundation-1","logokey":"$xvBICdlLlT9zQmGvk9haIT2bXJg0pY6tNIyz8Gj6XwQ4BfYvFkUzNb.jpeg","tagline":"The Cystic Fibrosis Foundation","urlname":"/mnc_page/cystic-fibrosis-foundation-1","isisraeli":0,"investorid":"zXKJZ6q2GKvIvWa9fUaYhCgf7JfYLiMAwbtMVaQUAuvVBEUvwyewBU","fundingtype":"Multinational","leadpartner":null,"investmentid":"w48D8V2IcnDTXPwf2HiB1QCK5Lz1NDP50Ai0s02mu7fEGXhZoWUogn","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$xvBICdlLlT9zQmGvk9haIT2bXJg0pY6tNIyz8Gj6XwQ4BfYvFkUzNb.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1tOiaORbzucZ8AdUNGHfLXLVQgrfXX0efXnmmHpKeVzojOPVIDcldt","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"OrbiMed","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ydAQAQ1hJDKnktnuZkM94XSvm6TE4QV0Nnv48SToSFeYOuTzkHNP0r","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODX8oueCww","date":"Mar 2021","amount":"$28.5M","source":"https://en.globes.co.il/en/article-cystic-fibrosis-treatment-co-splisense-raises-285m-1001371009","eventtype":"FundingRoundEvent","investment":[{"name":"OrbiMed","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"59210d30-0494-44db-aa0c-2b80e6bf80a8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","leadcaption":"","followupcaption":""},{"name":"Cystic Fibrosis Foundation","type":"NGO","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/cystic-fibrosis-foundation","logokey":"$iUPTjZCd6vbmBz2wuHZVqsuXDfpBeEK9liCnJWtZ1fS8GfXFPOltMt","tagline":"","urlname":"/company_page/cystic-fibrosis-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODXsv3DCww","fundingtype":"NGO","leadpartner":null,"investmentid":"925cf57f-6180-4468-b805-712c4aadcb10","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iUPTjZCd6vbmBz2wuHZVqsuXDfpBeEK9liCnJWtZ1fS8GfXFPOltMt","leadcaption":"","followupcaption":""},{"name":"Biotel","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/biotel","logokey":"$aajBtYwU6TpGNi16B7jLEIF2H6AgZPEdqmwBOGQd3RJ1Epr1atAb61","tagline":"Remote Cardiac Monitors","urlname":"/company_page/biotel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODD4L-bCww","fundingtype":"Company","leadpartner":null,"investmentid":"98f631fe-eabd-4a3e-8383-54fc75d7c89a","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$aajBtYwU6TpGNi16B7jLEIF2H6AgZPEdqmwBOGQd3RJ1Epr1atAb61","leadcaption":"","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"99b3d470-2018-4a41-af75-c5a04380c22a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bf47da0a-f70b-4a42-aed3-f5cea345f8f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":28500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCm2u2LCQw","date":"Feb 2020","amount":"Undisclosed","source":"https://israelbiotechfund.com/#Portfolio","eventtype":"FundingRoundEvent","investment":[{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"l6o0TV3Pw00qOcU5jHZkOfFyFu0eWtaxZj3QV07Tv4Ga9bxEyV5C59","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODWyPmECAw","date":"Nov 2018","amount":"$1M","source":"https://pitchbook.com/profiles/company/187929-01#timeline","eventtype":"FundingRoundEvent","investment":[{"name":"Integra Holdings","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"408ea50c-ca3c-410c-b6cc-76ca12dfc21a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"11/2016","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"SpliSense","logourl":"https://storage.googleapis.com/clean-finder-353810/$JS8BOpidhTStHuEfwGf2V21W0KNz5GXjgiN9ZmN2DYhE9sus6Sw3zY","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$JS8BOpidhTStHuEfwGf2V21W0KNz5GXjgiN9ZmN2DYhE9sus6Sw3zY","seoabout":"SpliSense is a clinical stage company developing transformative RNA-based treatments for unmet needs relating to diverse pulmonary diseases. Its treatment ...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"},{"title":"Biotechnology","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"bQLEeiU8IRxDxCkGBtEPBCCxeMk0gtqMyBg5ev63xt6dI30Pqss3nO","date":"Apr 2024","amount":"$12M","source":"https://www.globes.co.il/news/article.aspx?_atscid=7_134353_204082920_2566612_0_Txtetaxjxdshwhus8sp&did=1001476461","eventtype":"FundingRoundEvent","investment":[{"name":"Cystic Fibrosis Foundation","type":"Multinational","amount":8500000,"hidden":true,"country":"United States","fullurl":"/mnc_page/cystic-fibrosis-foundation-1","logokey":"$xvBICdlLlT9zQmGvk9haIT2bXJg0pY6tNIyz8Gj6XwQ4BfYvFkUzNb.jpeg","tagline":"The Cystic Fibrosis Foundation","urlname":"/mnc_page/cystic-fibrosis-foundation-1","isisraeli":0,"investorid":"zXKJZ6q2GKvIvWa9fUaYhCgf7JfYLiMAwbtMVaQUAuvVBEUvwyewBU","fundingtype":"Multinational","leadpartner":null,"investmentid":"w48D8V2IcnDTXPwf2HiB1QCK5Lz1NDP50Ai0s02mu7fEGXhZoWUogn","fundingsubtype":null,"investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$xvBICdlLlT9zQmGvk9haIT2bXJg0pY6tNIyz8Gj6XwQ4BfYvFkUzNb.jpeg","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"Lead ","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":null,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"1tOiaORbzucZ8AdUNGHfLXLVQgrfXX0efXnmmHpKeVzojOPVIDcldt","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "},{"name":"OrbiMed","type":"Investor","amount":null,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"ydAQAQ1hJDKnktnuZkM94XSvm6TE4QV0Nnv48SToSFeYOuTzkHNP0r","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Undisclosed Round","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":12000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODX8oueCww","date":"Mar 2021","amount":"$28.5M","source":"https://en.globes.co.il/en/article-cystic-fibrosis-treatment-co-splisense-raises-285m-1001371009","eventtype":"FundingRoundEvent","investment":[{"name":"OrbiMed","type":"Investor","amount":0,"hidden":false,"country":"United States","fullurl":"/investor_page/orbimed","logokey":"$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","tagline":null,"urlname":"/investor_page/orbimed","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKGWppMKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"59210d30-0494-44db-aa0c-2b80e6bf80a8","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YdYRiJO5uDKRYVV4ljtlt361skiLJyDfu6DOVXBmeHHKhWCPE7itwN","leadcaption":"","followupcaption":""},{"name":"Cystic Fibrosis Foundation","type":"NGO","amount":0,"hidden":false,"country":"United States","fullurl":"/company_page/cystic-fibrosis-foundation","logokey":"$iUPTjZCd6vbmBz2wuHZVqsuXDfpBeEK9liCnJWtZ1fS8GfXFPOltMt","tagline":"","urlname":"/company_page/cystic-fibrosis-foundation","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODXsv3DCww","fundingtype":"NGO","leadpartner":null,"investmentid":"925cf57f-6180-4468-b805-712c4aadcb10","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$iUPTjZCd6vbmBz2wuHZVqsuXDfpBeEK9liCnJWtZ1fS8GfXFPOltMt","leadcaption":"","followupcaption":""},{"name":"Biotel","type":"Company","amount":0,"hidden":true,"country":"United States","fullurl":"/company_page/biotel","logokey":"$aajBtYwU6TpGNi16B7jLEIF2H6AgZPEdqmwBOGQd3RJ1Epr1atAb61","tagline":"Remote Cardiac Monitors","urlname":"/company_page/biotel","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODD4L-bCww","fundingtype":"Company","leadpartner":null,"investmentid":"98f631fe-eabd-4a3e-8383-54fc75d7c89a","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$aajBtYwU6TpGNi16B7jLEIF2H6AgZPEdqmwBOGQd3RJ1Epr1atAb61","leadcaption":"","followupcaption":""},{"name":"Integra Holdings","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"99b3d470-2018-4a41-af75-c5a04380c22a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":"Follow on "},{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"bf47da0a-f70b-4a42-aed3-f5cea345f8f6","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":"Follow on "}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":28500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCm2u2LCQw","date":"Feb 2020","amount":"Undisclosed","source":"https://israelbiotechfund.com/#Portfolio","eventtype":"FundingRoundEvent","investment":[{"name":"Israel Biotech Fund","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/israel-biotech-fund","logokey":"$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","tagline":null,"urlname":"/investor_page/israel-biotech-fund","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwPKL6cUKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"l6o0TV3Pw00qOcU5jHZkOfFyFu0eWtaxZj3QV07Tv4Ga9bxEyV5C59","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YILqEmtVuPhOAI5dVRC7PIVBwe49xO4KSX6J9OAMZzEcIhU9plZyEZ","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODWyPmECAw","date":"Nov 2018","amount":"$1M","source":"https://pitchbook.com/profiles/company/187929-01#timeline","eventtype":"FundingRoundEvent","investment":[{"name":"Integra Holdings","type":"Investor","amount":1000000,"hidden":false,"country":"Israel","fullurl":"/investor_page/integra-holdings","logokey":"$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","tagline":null,"urlname":"/investor_page/integra-holdings","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwNfNo5oLDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"408ea50c-ca3c-410c-b6cc-76ca12dfc21a","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZrMXDGqLAjIaNETN2Il08IVyKZSqBMoFclFz61juF7eIIYUw9iz4Ow","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}